Gilead Sciences Inc.’s remdesivir had little or no effect on Covid-19 patients’ length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) found.
A roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, the illness caused by the virus.
The anti-malaria drug touted by U.S. President Donald Trump as a Covid-19 treatment was ineffective for patients with a mild version of the disease in a study conducted by researchers at the University of Minnesota.
The World Health Organization is discontinuing the WHO’s trials of the malaria drug hydroxychloroquine and the combination HIV drug lopinavir/ritonavir in hospitalized patients with COVID-19 after they failed to reduce mortality.
A global trial designed to test whether the anti-malaria drugs hydroxychloroquine and chloroquine can prevent infection with COVID-19 is to restart after being approved by British regulators.
New information released by GlobalData showed that there are now more than 718 pipeline drugs associated with COVID-19.
The U.S. Food and Drug Administration issued a warning to healthcare providers against administering the malaria drug hydroxychloroquine or chloroquine in combination with Gilead Sciences’ experimental COVID-19 drug, remdesivir.
The U.S. Food and Drug Administration revoked the emergency use authorization for the malaria drug hydroxychloroquine as a treatment for COVID-19.
An article raising concern about the safety of using hydroxychloroquine as a treatment of COVID-19 that forced the World Health Organization to temporarily suspend a clinical study involving the drug was retracted.
Scientists resumed COVID-19 trials of the now world-famous drug hydroxychloroquine, as confusion continues to reign about the anti-malarial hailed by U.S. President Donald Trump as a potential “game-changer” in fighting the pandemic.